Organon & Co. audit committee completes review of biosimilar purchase timing
Organon & Co.'s audit committee has completed an independent review of the timing of its biosimilar purchases from a prior supplier, concluding that no improper conduct occurred and no financial statement adjustments are needed. This review follows recent news of the company's fourth-quarter 2025 earnings shortfall, where both EPS and revenue fell below expectations. Organon plans to file its Form 10-K for 2025 on time.
Organon shares jump 6% after audit finds no misconduct
Organon & Co. (NYSE:OGN) shares increased by 6% after its audit committee completed an independent review that found no improper conduct related to biosimilar purchases from a supplier in prior years. The review, conducted with outside counsel, determined no action is required and found no evidence of misconduct or need for financial statement adjustments. Organon plans to timely file its Form 10-K for the year ended December 31, 2025.
Organon Audit Review Finds No Issues, 10-K On Track
Organon announced that an independent review by its Board's Audit Committee found no improper conduct regarding its past biosimilar purchases and no need to restate financial statements. The company expects to file its 2025 Form 10-K on time, reassuring investors about its financial reporting and internal controls. TipRanks' AI Analyst, Spark, rates OGN as Neutral, citing high leverage and declining profitability, offset by an inexpensive valuation and a 3.59% dividend yield.
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage
Organon announced its financial targets for 2026, projecting flat revenues of $6.2 billion and an EBITDA of $1.9 billion. The company plans to achieve these targets through cost controls, a greater focus on its women's health portfolio, and a strategy to offset biosimilar competition in its established brands segment.
5 Revealing Analyst Questions From Organon's Q4 Earnings Call
Organon's Q4 CY2025 earnings call highlighted operational challenges, pricing pressure, and product mix shifts, leading to negative market reaction despite in-line revenue. Analysts probed management on issues including internal investigations, biosimilar guidance impacts, cost savings efficacy, long-term margin trends, and competitive positioning of key products. Future catalysts include cost reduction, Nexplanon's global performance, stabilization of established brands, and debt reduction.
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
Shares of Amphastar Pharmaceuticals (AMPH), Novavax (NVAX), and Organon (OGN) all saw significant jumps following a softer-than-expected January Consumer Price Index (CPI) report. The lower inflation data fueled hopes for earlier interest rate cuts by the Federal Reserve, which generally supports stock valuations. Although Amphastar's shares had been volatile and recently faced a price target cut, all three companies experienced gains in reaction to the positive economic news.
Organon & Co. Plans Quarterly Dividend of $0.02 (NYSE:OGN)
Organon & Co. (NYSE:OGN) announced a quarterly dividend of $0.02 per share, payable on March 12th to shareholders of record on February 23rd. Despite this dividend, the company's shares traded down 7.9% after reporting Q4 earnings of $0.63 EPS, missing analyst estimates, and a 5.3% year-over-year revenue decline. Analysts have largely downgraded the stock, with an average rating of "Reduce" and a target price of around $8.38.
Organon & Co To Go Ex-Dividend On February 23rd, 2026 With 0.02 USD Dividend Per Share
Organon & Co (OGN.US) is scheduled to go ex-dividend on February 23rd, 2026, with shareholders of record on that date set to receive a cash dividend of $0.02 per share on March 12th, 2026. The article also provides general definitions of cash and stock dividends, clarifying their implications for investors. It emphasizes that dividend information is for reference and not guaranteed, and advises consulting a tax professional for specific tax advice.
Organon & Co. (NYSE:OGN) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS
Organon & Co. (NYSE:OGN) announced its quarterly earnings, reporting an EPS of $0.63, missing analyst estimates by $0.11. The company's revenue was $1.51 billion, slightly below expectations, and showed a 5.3% year-over-year decrease. Organon outlined strategic financial adjustments including a dividend cut, asset sale, and cost savings to reduce debt, while facing headwinds with its Nexplanon product and receiving a consensus "Reduce" rating from analysts.
Earnings call transcript: Organon Q4 2025 reveals EPS miss, stock drops 10.8%
Organon & Co reported a significant Q4 2025 EPS miss at $0.63 against a forecasted $0.76, with revenue also falling short at $1.51 billion. This underperformance led to a 10.79% drop in its stock price during premarket trading. Despite challenges, the company focused on debt reduction, cost savings, and extended its Nexplanon duration, while forecasting 2026 revenue and adjusted EBITDA to remain consistent with 2025 levels.
Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook
Organon & Co (NYSE:OGN) shares dropped sharply after reporting mixed Q4 2025 results, missing EPS estimates due to significant gross margin contraction and a non-cash goodwill impairment charge. While revenue largely met expectations, the company's flat 2026 outlook for both revenue and Adjusted EBITDA disappointed investors, suggesting a period of stabilization rather than growth. The market reacted negatively to the profitability challenges and cautious guidance, leading to an approximate 8% decline in pre-market trading.
Organon falls as women’s health unit drives Q4 miss (OGN:NYSE)
Organon (OGN) stock dropped approximately 11% in premarket trading after its Q4 2025 financial results missed Street forecasts. The underperformance was primarily driven by its Women’s Health segment. The company reported adjusted earnings per share of $0.63.
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations
Organon (NYSE:OGN) reported Q4 CY2025 results, meeting Wall Street’s revenue expectations with $1.51 billion, though sales declined 5.3% year-on-year. The company's non-GAAP EPS of $0.63 missed analyst estimates by 13.3%, and its operating margin significantly decreased to -9.8%. Despite a slight beat on full-year revenue guidance, the company faces challenges with flat revenue growth over the last two to five years and a projected revenue decline for the next 12 months.
Earnings snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook
Organon & Co. missed its bottom-line estimates in a recent earnings report. The pharmaceutical company also initiated its financial outlook for fiscal year 2026. This indicates a focus on future performance despite the recent earnings miss.
Organon: Q4 Earnings Snapshot
Organon & Co. (OGN) reported a fourth-quarter loss of $205 million, or 79 cents per share, missing Wall Street expectations. Adjusted earnings were 63 cents per share, falling short of the average analyst estimate of 73 cents. The pharmaceutical company also missed revenue forecasts, posting $1.51 billion against an expected $1.52 billion, and projects full-year revenue of $6.2 billion.
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
Organon announced its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of $6.2 billion, down 3% year-over-year, and diluted earnings per share of $0.72. The company forecasts approximately $6.2 billion in revenue and $1.9 billion in Adjusted EBITDA for full-year 2026, consistent with 2025 performance. Organon also declared a quarterly dividend of $0.02 per share and disclosed an Audit Committee review concerning the timing of biosimilar purchases from a supplier in prior years.
Organon Earnings: What To Look For From OGN
Organon (NYSE: OGN) is set to announce its earnings results, with analysts expecting a 5.2% year-on-year revenue decline to $1.51 billion and adjusted earnings of $0.73 per share. The company has a history of beating revenue estimates, and peer performance from Eli Lilly and Bristol-Myers Squibb shows mixed but generally positive results. The stock has been flat over the last month amid market volatility, with an average analyst price target of $9.36.
Down 72% In 3 Years, Can Organon Stock Finally Recover In 2026?
Organon & Co. (OGN) stock has fallen 72% in three years, but a new analysis suggests it could recover. Despite leadership changes, an internal investigation, and divestitures, the women's health and biosimilars company is projected to see its stock rise to $12.67 by December 2029, representing a 53% total return. This forecast is based on strategies like debt reduction, international Nexplanon growth, and the performance of newer biosimilar products, aiming for an 11.5% annual growth over the next 3.9 years.
Organon & Co (OGN.US) will release its earnings report before the market opens on February 12.
Organon & Co (OGN.US) is scheduled to release its earnings report before the market opens on February 12. The article provides past financial performance for Q3 2025 and Q4 2024, noting revenues of $1.602 billion and $1.592 billion respectively. Investors are advised to stay tuned for the upcoming report and earnings call.
Organon & Co: Can This Beaten-Down Women’s Health Specialist Finally Turn a Corner?
Organon & Co's stock has been in a brutal multi-quarter slide, trading near its 52-week low despite its steady cash generation from women's health and legacy brands. While recent quarterly results and guidance were modest, Wall Street analysts hold a mixed view, with some seeing value in its low valuation and firm dividend, while others remain cautious due to structural headwinds. The company's future hinges on demonstrating consistent growth in its women's health and biosimilar segments and making significant balance sheet progress to overcome investor skepticism.
Organon & Co: Can This Beaten-Down Women’s Health Specialist Finally Turn a Corner?
Organon & Co's stock has been on a significant downward trend, hitting near 52-week lows, despite the company generating steady cash from its women's health and legacy brands. While recent quarterly results were in line with expectations and analysts maintain mixed but constructive ratings with modest upside targets, the market remains cautious. Investors are looking for clearer growth visibility in women's health and biosimilars, alongside continued balance sheet progress, to determine if the stock can reverse its fortunes.
Organon & Co. (NYSE:OGN) Lowered to Strong Sell Rating by Zacks Research
Zacks Research has downgraded Organon & Co. (NYSE:OGN) to a "strong sell" rating, with other analysts also issuing negative ratings, leading to a consensus "Reduce" rating and an average price target of $8.38. Despite beating recent quarterly earnings and revenue estimates, the company faces concerns due to a very high debt-to-equity ratio of 9.69. Institutional investors hold a significant 77.4% of the stock.
Roche Settles Perjata Patent Suit on Organon, Henlius Biosimilar
Roche, through its subsidiaries Genentech Inc. and Hoffmann-La Roche Inc., has settled a patent infringement lawsuit concerning the breast-cancer drug Perjeta with Shanghai Henlius Biotech Inc. and Organon & Co. The agreement, filed in federal court, leads to the dismissal of all claims and counterclaims, effectively ending the litigation over the biosimilar version of the drug. No specific details about the settlement terms were disclosed.
What Does the Market Think About Organon & Co?
Organon & Co's short interest has increased by 5.76% to 17.55 million shares, representing 9.0% of its float. While this indicates a more bearish sentiment from some investors, the company's short interest is slightly below its peer group average of 9.07%. Traders should be aware of this increase in shorted shares, though it doesn't guarantee a near-term price drop.
Roche Settles Perjeta Patent Suit on Organon, Henlius Biosimilar
Roche Holding AG subsidiaries have settled a patent infringement lawsuit against Shanghai Henlius Biotech Inc. and Organon & Co. concerning their biosimilar version of the breast-cancer drug Perjeta. All claims and counterclaims have been dismissed by agreement, as stated in a federal court filing, though no further details about the settlement were provided. The US Food and Drug Administration had previously approved the biosimilar.
The Market Lifts Organon & Co. (NYSE:OGN) Shares 25% But It Can Do More
Organon & Co. (NYSE:OGN) shares have recently gained 25%, yet they are still down 44% over the last year. Despite a low P/E ratio of 4.6x compared to the broader market, the company's earnings have decreased by 62% in the last year, raising questions about its valuation. However, analysts predict a 20% annual earnings growth for Organon over the next three years, outpacing the market's expected 12% growth, suggesting potential undervaluation if future growth materializes.
The Market Lifts Organon & Co. (NYSE:OGN) Shares 25% But It Can Do More
Organon & Co. (NYSE:OGN) shares have recently gained 25%, though they are still down 44% over the last year. Despite a low P/E ratio of 4.6x compared to the broader market, the company's earnings have decreased by 62% in the last year and 52% over three years. Analysts, however, predict a future earnings growth of 20% per year over the next three years, which is higher than the market's expected 12%.
Organon Completes Divestiture of JADA System to Laborie Medical
Organon announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. for up to $465 million. This divestiture strengthens Organon's balance sheet, supports its capital allocation strategy for women's health biopharmaceuticals, and is expected to facilitate debt reduction. The deal also aims to expand global access to the JADA System, a medical device for managing postpartum hemorrhage, through Laborie's expertise in maternal health.
Organon Completes Divestiture of JADA System to Laborie Medical
Organon (OGN) has completed the divestiture of its JADA System to Laborie Medical Technologies Corp. for up to $465 million, an agreement expected to strengthen Organon's balance sheet for growth opportunities in women’s health biopharmaceuticals. The deal includes a payment of $440 million at closing and a potential earn-out of up to $25 million with approximately 100 employees transferring to Laborie. This strategic move aims to expand global access to the JADA System, a widely used treatment for postpartum hemorrhage, and to reduce Organon’s debt while simplifying its portfolio.
Y Intercept Hong Kong Ltd Invests $2 Million in Organon & Co. $OGN
Y Intercept Hong Kong Ltd disclosed a new $2 million stake in Organon & Co. (NYSE:OGN) during the third quarter, acquiring 187,253 shares. The pharmaceutical company, which recently reported better-than-expected Q3 earnings and revenue, has seen increased institutional investment from firms like Norges Bank and AQR Capital Management. Despite some analysts trimming price targets and a consensus "Reduce" rating, Organon currently offers a 0.9% dividend yield.
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
Organon (NYSE: OGN) is set to release its fourth quarter and full year 2025 financial results on February 12, 2026, followed by a webcast and conference call at 8:30 a.m. ET. The company does not anticipate recording any milestone expense in Q4 2025, though results are subject to finalization. Interested parties can access the live webcast or a replay on Organon's investor relations website and participate in the call by dialing the provided numbers.
Organon Completes Divestiture of JADA® System to Laborie
Organon (NYSE: OGN) announced the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. The JADA® System is designed for the control and treatment of abnormal postpartum uterine bleeding or hemorrhage. Organon, a global healthcare company, focuses on women's health and general medicines, aiming to deliver impactful solutions for a healthier everyday.
Organon (OGN) Stock Sinks As Market Gains: What You Should Know
Organon (OGN) stock experienced a 1.1% decline while the broader market saw gains. Despite this daily dip, the pharmaceutical company's shares have risen nearly 28% over the past month, outperforming the Medical sector. Analysts anticipate a year-over-year decline in Organon's upcoming earnings and revenue, but a "Hold" Zacks Rank indicates a neutral outlook.
543,711 Shares in Organon & Co. $OGN Purchased by Sector Gamma AS
Sector Gamma AS recently purchased 543,711 shares of Organon & Co. (NYSE:OGN), representing about 1.4% of its total holdings and making it their 27th largest position. Despite this significant institutional investment, analyst sentiment toward Organon is generally bearish, with an average "Reduce" rating and a target price of $8.38. The company reported an earnings beat and strong revenue, trades at a low P/E ratio, and has a market cap of approximately $2.54 billion.
Sun Pharma Bid Puts Organon Valuation And Growth Prospects In Focus
Sun Pharmaceutical Industries has made a non-binding offer to acquire Organon (NYSE: OGN), potentially marking the largest cross-border acquisition by an Indian pharmaceutical company. This proposed deal, which would expand Sun Pharma's presence in women's health and biosimilars, has brought Organon's valuation and growth prospects into sharp focus. Organon's stock has seen significant recent gains following the news, despite prior declines, and is currently trading just above analyst targets but is flagged as undervalued by Simply Wall St.
Sun Pharma is said to mull bid for women’s wellness firm Organon
Sun Pharmaceutical Industries Ltd. is reportedly considering a bid for the New York-listed women's wellness company Organon & Co. The Indian pharmaceutical giant is in preliminary discussions with advisers and global lenders to arrange financing for a potential deal. Organon's shares recently rallied 8% following initial reports of Sun Pharma's interest, despite having fallen 40% over the past year.
Massachusetts Financial Services Co. MA Has $101.48 Million Stake in Organon & Co. $OGN
Massachusetts Financial Services Co. trimmed its stake in Organon & Co. by 7.2% during the third quarter, reducing its holdings to 9,502,102 shares valued at approximately $101.48 million. Despite institutional investors owning a significant portion of Organon, analyst sentiment remains largely negative with an average "Reduce" rating and a target price of $8.38, influenced by recent downgrades from several firms. Organon recently surpassed quarterly EPS and revenue expectations but faces concerns regarding its valuation, leverage, and offers a modest dividend yield.
Organon Stock (+8%): Sun Pharma Bid Rumors Spark an M&A Chase
Organon (OGN) stock rose 8% due to rumors that Indian pharmaceutical giant Sun Pharma is preparing a bid to acquire the company. This potential acquisition highlights Organon's attractiveness in the pharmaceutical M&A landscape, despite its previous spin-off from Merck. The speculation suggests a renewed interest in Organon's drug portfolio.
Why Are Organon (OGN) Shares Soaring Today
Organon (OGN) shares jumped 8.9% after reports that Sun Pharmaceutical Industries submitted a non-binding, all-cash proposal to acquire the company, backed by $10 billion to $14 billion in financing. This potential deal, if successful, would be the largest cross-border acquisition by an Indian pharmaceutical firm, aiming to expand Sun Pharma's presence in women's health and biosimilars markets. Despite the positive market reaction, Organon's shares are still significantly below their 52-week high from January 2025.
Organon Stock Surges After FDA Nod for Nexplanon Expansion
Organon & Co. (NYSE: OGN) saw its stock rise by 8.22% following the FDA's supplemental approval to extend the use of its contraceptive Nexplanon for up to five years. This regulatory success, combined with a new strategic partnership with Daiichi Sankyo Europe for the cardiovascular drug Nilemdo, has fueled investor optimism and contributed to a bullish trend in the company's financial performance. The article highlights Organon's strong fiscal year 2025 revenue and gross margin, indicating efficient management and robust profitability.
Sun Pharmaceutical Makes Non-Binding Offer to Acquire Organon for $10B-$14B
Sun Pharmaceutical has made a non-binding offer of $10 billion to $14 billion to acquire Organon, backed by significant bridge loans. The acquisition is expected to be an all-cash transaction, with due diligence commencing soon. Despite this, Wall Street analysts generally forecast a decline in Organon's stock price over the next year, with an average target of $8.50 USD.
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
Sun Pharmaceutical Industries Ltd is reportedly considering acquiring Organon & Co, a U.S.-based women's healthcare company, in what could be the largest cross-border deal by an Indian drugmaker. Sun Pharma has submitted a non-binding all-cash bid and secured financing of $10–14 billion, with the transaction potentially valued at about $10 billion including debt. This acquisition would significantly expand Sun Pharma's presence in the U.S. market and women's health sector, despite Organon's recent divesting of non-core assets and existing debt of $8.9 billion.
Organon gains on report of Sun Pharmaceutical interest
Organon's stock price increased following a report indicating that Sun Pharmaceutical Industries is exploring a potential acquisition of the company. This news has created speculation about the future of Organon and its pharmaceutical assets.
Why Are Organon (OGN) Shares Soaring Today
Shares of Organon (OGN) jumped 8.9% following reports that Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the company for an estimated $10 billion to $14 billion. This potential all-cash deal, if successful, would be the largest cross-border acquisition by an Indian pharmaceutical firm and aims to expand Sun Pharma's presence in women's health and biosimilars. Despite today's rise, Organon's shares are still significantly below their 52-week high, and the stock has been volatile over the past year.
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years
Organon has received FDA approval to extend the use of its contraceptive implant, NEXPLANON, from three to five years. This approval is supported by clinical trial data demonstrating sustained efficacy and safety across diverse body weights, including those with higher BMIs, for the extended duration. This development aims to enhance NEXPLANON's competitive position by offering greater convenience and broadening its market reach in women's health.
Sun Pharmaceutical Evaluates Organon Acquisition to Scale US Business
Sun Pharmaceutical Industries, India's largest drugmaker, is reportedly considering acquiring US-based Organon, a company focusing on women's health and biosimilars. This potential $10 billion acquisition would be Sun Pharma's largest cross-border deal, aiming to significantly expand its presence and strengthen its portfolio in the competitive US market, particularly in high-growth segments. The move would mark a decisive step in reshaping Sun Pharma's global footprint, following its 2023 acquisition of Concert Pharmaceuticals.
Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever
Sun Pharmaceutical Industries Ltd has submitted a non-binding, all-cash offer to acquire US-based Organon, backed by $10-14 billion in acquisition financing, marking its most significant global expansion effort. This potential deal aims to enhance Sun Pharma's presence in women's health biopharma and biosimilars and would be the largest acquisition by an Indian pharmaceutical company if successful. Organon, which was spun off from MSD in 2021 and has substantial debt, is seeking a buyer and has been focusing on its women's health biopharma portfolio.
Sun Pharma says talk of $10bn Organon bid is 'speculative'
Sun Pharma has denied a rumor reported in The Economic Times about a potential $10 billion bid for women's health specialist Organon, calling the information "speculative." The Indian pharmaceutical giant, known for accelerating growth through M&A, stated it adheres to high governance standards and would disclose any material events. Organon, spun out from MSD/Merck & Co in 2021, focuses on women's health and biosimilars, and recently experienced leadership changes.
Sun Pharma terms $10 billion Organon acquisition reports 'speculative'
Sun Pharmaceutical Industries has labeled reports of its potential $10 billion acquisition of US-based Organon as "speculative." The Indian drugmaker stated there is no material information requiring disclosure to stock exchanges, emphasizing its adherence to governance and disclosure standards. This clarification follows media speculation about a significant cross-border deal that would boost Sun Pharma's US footprint and biosimilars portfolio.
Sun Pharma terms $10-billion Organon buy report as 'speculative'
Sun Pharma has deemed a news report about its potential $10-billion acquisition of US drugmaker Organon as "speculative." The Economic Times reported that Sun Pharma was evaluating a takeover, which would mark India's largest overseas acquisition in the pharmaceutical sector and expand Sun Pharma's presence in the US, women's health, and biosimilars. Organon, which was spun off from Merck in 2021, has been divesting assets to streamline its balance sheet.
